2126-2137
Novel 16-benzylidine substituted steroidal oximes in
the androstene series have been designed, synthesized and evaluated for in
vitro antineoplastic activity at NCI, Bethesda,
USA against
3-cell lines using one dose primary anticancer assay. Of the compounds tested,
3β-hydroxy derivatives 24 (DPJ-1059),
26 (DPJ-1081), 28 (DPJ-870), 30 (DPJ-818), 32 (DPJ-854)
and 3β-acetoxy derivatives 25
(DPJ-1061), 27 (DPJ-1083), 31 (DPJ-817) and 33(DPJ-900) have been found to be quite active.</smarttagtype